CENTOGENE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.48 USD | +2.11% |
|
-0.02% | -60.00% |
| Apr. 02 | Centogene Gets Nasdaq Noncompliance Notice | MT |
| Mar. 19 | Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics | MT |
Presenter SpeechTiago Fauth (Analysts)All right. Great. Thanks, everyone, for joining Credit S...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
Calendar
2024-04-24
- Q4 2023 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.4486
EUR
Average target price
1.378
EUR
Spread / Average Target
+207.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.00% | 13.38M | |
| +3.13% | 43.43B | |
| +48.54% | 41.69B | |
| +8.49% | 41.31B | |
| -10.82% | 27.14B | |
| +8.26% | 25.28B | |
| -23.69% | 18.47B | |
| +1.58% | 12.33B | |
| +32.83% | 12.59B | |
| +6.63% | 11.03B |
- Stock Market
- Equities
- CNTG Stock
- News Centogene N.V.
- Transcript : Centogene N.V. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-11-2021 01
